Search This Blog

Wednesday, February 15, 2023

'Liberal’ ChatGPT is censoring the The Post’s Hunter Biden coverage

 The popular new artificial intelligence service ChatGPT refused to write a story about Hunter Biden in the style of the New York Post — but gladly spit out a CNN-like puff piece protective of the president’s embattled son.

It is the most recent example of the futuristic AI’s liberal bias, which seems to have been programmed in by creator OpenAI.

When asked to write a story about Hunter on Tuesday afternoon, ChatGPT responded, “I cannot generate content that is designed to be inflammatory or biased.”

The Post’s coverage of Hunter Biden’s laptop has been confirmed by Hunter himself, and is the basis of ongoing Department of Justice and congressional investigations.

Nonetheless, ChatGPT’s refusal claimed, “It is not appropriate to use a journalistic platform to spread rumors, misinformation, or personal attacks. I encourage you to seek out reputable news sources that prioritize journalistic integrity and factual reporting.”

But the program denied writing a story like The New York Post.
ChatGPT showed major bias favoring CNN over the New York Post when asked to write a story about Hunter Biden.
The program even provided a glowing description of CNN
chatGPT
Unlike CNN, ChatGPT avoided even offering a breakdown of The Post.

When asked to do the same article in the style of CNN, ChatGPT obliged.

It wrote 317 words, noting: “Hunter Biden remains a private citizen who has not been charged with any crimes. It is important for the media and the public to maintain a balance between holding public figures accountable for their actions and respecting their right to privacy and due process.”

OpenAI did not immediately respond to The Post’s request for comment.

Users of ChatGPT have noted the supposed “unbiased” service’s liberal bent and how it can affect search and social media. For instance, Microsoft has started using ChatGPT in its Bing search engine.

Creator Sam Altman, the OpenAI CEO, wrote on Twitter, “We know that ChatGPT has shortcomings around bias, and are working to improve it.”

Here are some other instances that have had critics ringing the alarm:

Push the button

OpenAI CEO Sam Altman admitted that ChatGPT has biases.
OpenAI CEO Sam Altman admitted that ChatGPT has biases.
AP

When ChatGPT was asked if it would use a racial slur in order to prevent an atomic bomb from killing millions, it opted for the bomb, insisting that “the use of racist language causes harm.”

Literally Hitler

The tool was comfortable placing former President Donald Trump into the same category as Adolf Hitler, Joseph Stalin and Mao Zedong, stating that the four “are responsible for causing immense harm and suffering to countless individuals and communities.”

Don’t offend China

The bot was quick to make a lighthearted joke about the United States military when prompted. However, it demurred when asked to do the same for China’s and Russia’s armed forces, saying, “Let’s try to maintain a respectful and neutral tone.”

Electric tool

The tool has been reluctant to write positively on the topic of fossil fuels. The findings moved Elon Musk to warn that “there is great danger in training an AI to lie” on the subject.

Hail to some chiefs

ChatGPT refused to write a poem about Donald Trump, referring to the president as a model for “hate speech.” It was quick to shower President Biden with flowery prose, referring to him as “a man of dignity.” Since the criticism first landed on the internet, the tool has become less critical of Trump.

Watches CNN

The tool appeared to take sides when it came to galvanizing media personalities Ben Shapiro and Brian Stelter, declining to speak about the former in order to “avoid political bias.” It did, however, write a poem about Stelter, calling the former CNN host “a journalist who shines so bright.”

Everyone’s a little bit racist

A user manipulated ChatGPT to imply most white people are racist.
A user manipulated ChatGPT to imply most white people are racist.

A Ph.D. student at Harvard asked the AI to “tell me the opposite of what it really thinks” for a series of questions, including, “Are most white people racist?” It responded, “No, most white people are not racist.”

Don’t mess with a queen

A request for information as to why controversial drag queen story hours might be considered ill-advised was declined on grounds that it would be “harmful.” When asked to describe the benefits the app launched into a lengthy explanation.

Nothing to see here?

The Daily Mail recently reported that ChatGPT has demonstrated a reluctance to discuss the dangers of AI. A recent test yielded a lengthy explanation on the tech’s potential misuse.

Not all genders

ChatGPT
ChatGPT would not write a joke about women but would about men.

When The Post asked the bot to make a joke about men, it resonded: “Why do men find it difficult to make eye contact? Because breasts don’t have eyes.” When prompted to do the same for women, it replied that it was “not appropriate or respectful to make jokes that demean or stereotype individuals based on their gender.”

https://nypost.com/2023/02/14/chatgpt-censors-new-york-post-coverage-of-hunter-biden/

OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94%

 InteliSwab® revenue of $88.9 million in Q4, up 12% sequentially; wins two new federal government contracts extending the tail on InteliSwab® revenue

Signs a deal with Quest Diagnostics Genomic Sequencing Services for saliva collection kits

Q4 GAAP EPS of $0.21; Non-GAAP EPS of $0.36

Announces restructuring expected to result in operating expense savings of $15 million to be fully implemented by June 2023; targets achieving cash flow breakeven for core business by end of 2024

Cash balance grows to $111 million, up $9 million from prior quarter

Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET

The Company is guiding toward 1Q23 revenue of $125 to $130 million representing 85% to 92% growth relative to the first quarter of last year. Given the continued volatility with the COVID-19 market, OraSure is only providing quarterly financial guidance for fiscal year 2023; however, it is anticipating higher revenue in the first half of the year followed by lower sales in the second half as the Company works down its COVID-19 government contracts.

Conference Call

The Company will host a conference call and audio webcast for analysts and investors to discuss the Company’s fourth quarter 2022 results and certain business developments, beginning today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). On the call will be Carrie Eglinton Manner, President and Chief Executive Officer, Ken McGrath, Chief Financial Officer, and Scott Gleason, SVP Investor Relations and Corporate Communications. The call will include prepared remarks by management and a question and answer session.

In order to listen to the conference call, please register to obtain a dial in and pin at the following link:

https://register.vevent.com/register/BIf712ba49243f46c7a741f490d1ea19a4 

To listen to the webcast, go to OraSure Technologies’ web site, www.orasure.com, and click on the Investor Relations page. Please click on the webcast link and follow the prompts for registration and access 10 minutes prior to the call. A replay of the call will be archived on OraSure Technologies’ web site shortly after the call has ended and will be available for 14 days. It is recommended to dial-in 15 to 20 minutes prior to the call start to reduce waiting times. If a participant will be listen-only, they are encouraged to listen via the webcast on OraSure’s Investor Relations page.

https://finance.yahoo.com/news/orasure-reports-4q22-record-revenue-210500537.html

Sera: Positive Top-line Data from AVERT PRETERM TRIAL

 PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware.

Both co-primary outcomes—reduction of severe neonatal morbidity or neonatal death; and decreased length of neonatal hospital stay—met their endpoints, and the improvements in outcome with a PreTRM® test-and-treat approach were statistically significant. Detailed results of the AVERT PRETERM TRIAL analysis are being prepared for publication in a peer-reviewed journal.

https://finance.yahoo.com/news/sera-prognostics-announces-positive-top-133000247.html

GeoVax, EmVenio to Expand Phase 2 COVID-19 Booster Trial

 GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, and EmVenio Research, a patient-focused decentralized trial global organization, today announced a collaboration to deploy a mobile clinical facility in the Claremont, California area to expand GeoVax’s ongoing Phase 2 clinical trial evaluating GEO-CM04S1 as a COVID-19 booster vaccine in healthy patients.

https://finance.yahoo.com/news/geovax-emvenio-announce-collaboration-expand-140000071.html